Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
0R
0R1F.LSE
0R
0R1F.LSE
0R1F.LSE
News
·
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test
Mkt Cap
N/A
Volume
N/A
Next Earnings
N/A
Chart
Earnings
News
About
Dividends
Insider
Filings
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test
Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study. Continue Reading View Comments
finance.yahoo.com · Apr 22, 2025
Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test
Shares of Bristol Myers Squibb tumbled Wednesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study. Continue Reading View Comments
finance.yahoo.com · Apr 22, 2025
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the threshold for a statistically significant difference compared to placebo with an atypical antipsychotic for the primary endpoint of the change from baseline to Week 6 in the Positive and Negative Synd…
finance.yahoo.com · Apr 22, 2025
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 billion acquisition of MyoKardia for its obstructive hypertrophic myopathy (HCM) drug, Camzyos, in 2020, the pharmaceutical giant has had difficulty achie…
finance.yahoo.com · Apr 22, 2025
Bristol Myers says FDA updates Camzyos label to simplify treatment
Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has updated the U.S. Prescribing Information for Camzyos, simplifying treatment for patients and physicians by reducing the required echo monitoring for eligible patients in the maintenance phase and …
finance.yahoo.com · Apr 19, 2025
Bristol-Myers Squibb (NYSE:BMY) Gains FDA Approval To Simplify Camzyos Monitoring Process
Bristol-Myers Squibb recently announced an update from the FDA on CAMZYOS®, focusing on simplified treatment protocols and expanded patient eligibility, as well as an FDA approval for its Opdivo® and Yervoy® combination for specific cancer treatments. Despite these positive regul…
finance.yahoo.com · Apr 18, 2025
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label is supported by data including long-term clinical and real-world evidence which …
finance.yahoo.com · Apr 18, 2025
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
Bristol Myers Squibb stock skidded late Monday, tugging Cytokinetics lower, after Bristol's drug, Camzyos, failed in a heart disease study. Continue Reading View Comments
finance.yahoo.com · Apr 14, 2025
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
PRINCETON, N.J., April 14, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hyp…
finance.yahoo.com · Apr 14, 2025
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market
Shares of biotech stock Halozyme found support at their 200-day line in a time where many stocks are below this level. Continue Reading View Comments
finance.yahoo.com · Apr 11, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
0R
0R1F.LSE
0R1F.LSE
Buy
Sell
Market
Limit
Soon
0R1F.LSE
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any 0R1F.LSE yet.
Related Tickers
Earnings
Dividends
Last · Dec 31
Quarterly
Amount
$0.63
Yield
103.79%
Annual
$0.63